Dupuytren's Disease Market Outlook 2034 - Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

Dupuytren's Disease Market Summary
The Dupuytren's Disease market is projected to grow significantly from 2024 to 2034, driven by rising disease prevalence, greater awareness, and advancements in diagnosis and treatment. Currently, XIAFLEX (clostridium histolyticum) by Endo Pharmaceuticals remains the only FDA-approved therapy and is expected to see substantial uptake. Emerging pipeline assets, including adalimumab (180 Life Sciences) and VEN201 (Ventoux Biosciences), are anticipated to boost market expansion following potential approvals. Although existing treatments are limited by side effects, recurrence, and a lack of curative outcomes, the market is expected to advance at a strong CAGR through a combination of approved therapies and upcoming innovations during the forecast period.

DelveInsight's "Dupuytren's Disease Market Insights, Epidemiology, and Market Forecast-2034" report delivers a comprehensive understanding of Dupuytren's Disease, highlighting historical data and projected epidemiology, along with the market outlook for the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan. The latest market forecast study provides an extensive assessment of Dupuytren's Disease, presenting detailed insights into revenue patterns, disease prevalence, and the evolving treatment landscape. The report reviews critical Dupuytren's Disease statistics, current and future market size, as well as the advancement and effectiveness of upcoming therapeutic options. It also covers the pipeline of ongoing and planned clinical trials that are expected to influence the future treatment paradigm of Dupuytren's Disease. This makes the report an indispensable resource for analyzing market trends and the evolving therapeutic opportunities in this domain.

To learn more about the Dupuytren's Disease market forecast, treatment landscape, drug adoption, and epidemiological trends, Click here; Dupuytren's Disease Market Forecast - https://www.delveinsight.com/report-store/dupuytrens-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights of the Dupuytren's Disease Market Report
• The Dupuytren's Disease market size is projected to expand with a notable CAGR over the study period (2020-2034).
• In May 2025, Connext, a clinical stage biotechnology company, announced the successful completion of the dose escalation (Phase 1) part of its Phase 1/2 clinical trial for CNT201, its recombinant collagenase therapeutic for Dupuytren's contracture. The trial was conducted in an open-label format and confirmed both the safety and efficacy of CNT201: no dose-limiting toxicities were observed, and clear therapeutic benefits were demonstrated.
• In February 2025, Endo, Inc. (OTCQX: NDOI) announced today the launch of its new branded television commercial, Steve's Journey. The campaign, featuring a real Dupuytren's contracture patient, encourages patients to consult a hand specialist and ask about XIAFLEX® (collagenase clostridium histolyticum), the only FDA-approved nonsurgical treatment for Dupuytren's contracture.
• In July 2024, Connext announced the successful first dosing of CNT201, a therapeutic candidate for Dupuytren's contracture. The disease causes fibrosis in the fascia beneath the skin of the palm due to collagen buildup, resulting in permanently bent fingers that impair quality of life. Currently, no definitive cure exists for this condition.
• Key Companies in Dupuytren's Disease: Endo Pharmaceuticals/Asahi Kasei Pharma, 180 Life Sciences, Ventoux Biosciences, and others.
• Key Therapies in Dupuytren's Disease: XIAFLEX (clostridium histolyticum), Anti-TNF therapy adalimumab, VEN201, among others.
• The market growth is anticipated to accelerate due to the increasing prevalence of the disease and growing awareness. In addition, the introduction of multiple pipeline therapies across different stages is expected to significantly impact the market dynamics.
• A study by Broekstra et al. (2022) identified 38,707 individuals with Dupuytren's disease in a population-based cohort, reporting a point prevalence of 0.67% in 2013. Among them, 64.6% were male and 35.3% were female.
• Sasaki et al. (2021) conducted a study in Japan, identifying 44 individuals with Dupuytren's disease, corresponding to an overall prevalence of 3.9%. Prevalence was 8.3% in men and 1.3% in women. Among those over 60 years, the prevalence rose to 7.7%, with 18.5% in men and 2.4% in women.

Dupuytren's Disease Overview
Dupuytren's Disease, also referred to as Dupuytren's Contracture, is a progressive condition affecting the hand, where the connective tissue (fascia) under the palm skin thickens and contracts. Over time, this leads to one or more fingers-commonly the ring and little fingers-curving inward toward the palm, restricting extension.
The condition develops gradually and is more frequently observed in older adults, particularly males of Northern European descent. While generally painless, advanced cases can severely affect hand function and quality of life. Treatment options include non-surgical approaches such as injections, as well as surgical procedures to release the tightened tissue.

Get a Free sample for the Dupuytren's Disease Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/sample-request/dupuytrens-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Dupuytren's Disease Epidemiology
The epidemiology segment explores historical, present, and forecasted trends across the seven major markets (7MM) from 2020 to 2034. It provides clarity on the drivers of these trends by examining published studies and expert insights. It also offers an in-depth evaluation of diagnosed cases and anticipated shifts in the patient pool.

Dupuytren's Disease Epidemiology Segmentation:
The Dupuytren's Disease market report presents epidemiological data for 2020-2034 in the 7MM, segmented into:
• Total prevalence of Dupuytren's Disease
• Prevalence by severity
• Gender-based prevalence of Dupuytren's Disease
• Diagnosed cases of Episodic and Chronic Dupuytren's Disease

Download the full report to explore the factors influencing Dupuytren's Disease epidemiology @ Dupuytren's Disease Patient Pool- https://www.delveinsight.com/report-store/dupuytrens-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Dupuytren's Disease Drugs Uptake and Pipeline Activities
Adalimumab (180 Life Sciences):
180 Life Sciences is repurposing adalimumab (HUMIRA) for early-stage Dupuytren's contracture. Oxford studies suggest its anti-TNF action may prevent fibrous nodule growth. A Phase IIb trial, the first targeted therapy in early Dupuytren's, is complete. The UK MHRA requires a Phase III trial before approval, planned with a licensing partner in 2024.

VEN-201 (Ventoux Biosciences):
Ventoux Biosciences is developing VEN-201, a repurposed small molecule with proven safety, for Dupuytren's and Ledderhose disease. Preclinical results showed strong anti-fibrotic activity and safety. The company is fundraising to advance development, focusing on formulation, pre-clinical studies, and regulatory activities to fast-track this potential disease-modifying therapy.

Dupuytren's Disease Therapies and Key Companies
• XIAFLEX (clostridium histolyticum): Endo Pharmaceuticals/Asahi Kasei Pharma
• Adalimumab (Anti-TNF): 180 Life Sciences
• VEN201: Ventoux Biosciences

Discover more about therapies expected to capture major Dupuytren's Disease market share @ Dupuytren's Disease Treatment Landscape - https://www.delveinsight.com/sample-request/dupuytrens-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Dupuytren's Disease Market Drivers
• Growing awareness has contributed to earlier diagnosis and intervention.
• Advancements in both surgical and non-surgical treatments provide patients with more therapeutic options.

Dupuytren's Disease Market Barriers
• Rising interest in minimally invasive procedures offers potential for improved outcomes and reduced recovery times.
• Progress in genetics and precision medicine may enable personalized treatments, enhancing therapeutic effectiveness.

Scope of the Dupuytren's Disease Market Report
• Study Period: 2020-2034
• Geographic Coverage: 7MM [United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Companies: Endo Pharmaceuticals/Asahi Kasei Pharma, 180 Life Sciences, Ventoux Biosciences, and others
• Key Therapies: XIAFLEX (clostridium histolyticum), adalimumab, VEN201, and others
• Therapeutic Assessment: Current marketed therapies and emerging pipeline candidates
• Market Dynamics: Drivers and barriers shaping Dupuytren's Disease market growth
• Competitive Insights: SWOT, PESTLE, Porter's Five Forces, BCG Matrix, Market entry strategies
• Additional Insights: Unmet needs, KOL perspectives, analyst views, market access, and reimbursement outlook

To explore the companies involved in Dupuytren's Disease research and development, visit @ Dupuytren's Disease Clinical Trials and Therapeutic Assessment - https://www.delveinsight.com/sample-request/dupuytrens-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Introduction to Dupuytren's Disease Market Report
2. Executive Summary
3. SWOT Analysis
4. Patient Share (%) Overview
5. Market Overview
6. Disease Background and Overview
7. Epidemiology and Patient Population
8. Country-Specific Patient Population
9. Current Treatment and Medical Practices
10. Unmet Needs
11. Emerging Therapies
12. Market Outlook
13. Country-Wise Analysis (2020-2034)
14. Market Access and Reimbursement Landscape
15. Market Drivers
16. Market Barriers
17. Appendix
18. Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a prominent Healthcare Business Consulting and Market Research firm specializing in the life sciences sector. It supports pharmaceutical companies with complete end-to-end solutions to boost performance and growth.

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.